{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:39:31Z","timestamp":1792172371911,"version":"4.4.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have been proven to be beneficial in multiple advanced malignancies. However, the widespread use of ICIs also occurred with various immune-related adverse events (irAEs). Here, we first report a case of sintilimab-related cystitis\/ureteritis. A 53-year-old man with driver gene-negative pulmonary adenocarcinoma (cT<jats:sub>1c<\/jats:sub>N<jats:sub>3<\/jats:sub>M<jats:sub>1c<\/jats:sub>, Stage IVB) was being treated with sintilimab in combination of paclitaxel-albumin and bevacizumab as second-line treatment. He was hospitalized for haematuria, pollakiuria, painful micturition and low back pain after three courses. Urinalysis showed red blood cells (RBCs) and white blood cells (WBCs) were obviously increased, and serum creatinine (sCr) level was also significantly elevated. Urine culture and cytology were both negative, and cystoscopy revealed diffused redness of bladder mucosa. Urinary ultrasonography showed mild hydronephrosis and dilated ureter. The patient was diagnosed as immunotherapy-related cystitis\/ureteritis after a multidisciplinary team (MDT) meeting. Once the diagnosis was made, corticosteroid therapy was given, which rapidly resolved the patient\u2019s symptoms and signs. Computer tomography angiography (CTA) and CT urography (CTU) was conducted after sCr level was back to normal and demonstrated ureter dilation and hydroureter. Once symptoms relieved, bladder biopsy was performed and confirmed the bladder inflammation. The patient was subsequently switched to maintenance dose of methylprednisolone and tapered gradually. Since sintilimab has been used in advanced malignancies, we first reported a rare case of sintilimab-induced cystitis\/ureteritis and summarized sintilimab-related adverse events to improve the assessment and management of irAEs.<\/jats:p>","DOI":"10.3389\/fonc.2021.757069","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T11:57:25Z","timestamp":1640260645000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Case Report: A Case of Sintilimab-Induced Cystitis\/Ureteritis and Review of Sintilimab-Related Adverse Events"],"prefix":"10.3389","volume":"11","author":[{"given":"Lingfang","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The Blockade of Immune Checkpoints in Cancer Immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: First Global Approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-020-00250-z","article-title":"Recent Updates on Sintilimab in Solid Tumor Immunotherapy","volume":"8","author":"Liu","year":"2020","journal-title":"Biomark Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and Activity of Sintilimab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (ORIENT-1): A Multicentre, Single-Arm, Phase 2 Trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (Oncology Program by InnovENT Anti-PD-1-11)","volume":"15","author":"Yang","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2008","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated With Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-017-0298-6","article-title":"A Case of Cystitis After Administration of Nivolumab","volume":"6","author":"Ozaki","year":"2017","journal-title":"Int Cancer Conf J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2017.12.006","article-title":"Two Cases of Nonbacterial Cystitis Associated With Nivolumab, the Anti- Programmed-Death-Receptor-1 Inhibitor","volume":"17","author":"Shimatani","year":"2018","journal-title":"Urol Case Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.12286","article-title":"Improvement of Urinary Symptoms After Bladder Biopsy: A Case of Pathologically Proven Allergy-Related Cystitis During Administration of Nivolumab","volume":"4","author":"Yajima","year":"2021","journal-title":"IJU Case Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.12211","article-title":"Non-Bacterial Cystitis With Increased Expression of Programmed Death-Ligand 1 in the Urothelium: An Unusual Immune-Related Adverse Event During Treatment With Pembrolizumab for Lung Adenocarcinoma","volume":"3","author":"Ueki","year":"2020","journal-title":"IJU Case Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S321965","article-title":"Immunotherapy-Related Cystitis: Case Report and Review of the Literature","volume":"14","author":"Zhu","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051776","article-title":"Tissue Expression of PD-L1 Mediates Peripheral T Cell Tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J Exp Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A Review of Cancer Immunotherapy Toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2021.626748","article-title":"PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium","volume":"11","author":"Dowell","year":"2021","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep00317","article-title":"BALB\/c-Fcgr2b\u2013\/\u2013 Pdcd1\u2013\/\u2013 Mouse Expressing Anti-Urothelial Antibody Is a Novel Model of Autoimmune Cystitis","volume":"2","author":"Sugino","year":"2012","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.02076","article-title":"Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-Tumor Effect of Partial Regression","volume":"11","author":"Wen","year":"2020","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.12.030","article-title":"Marked Elevation of Creatine Phosphokinase Alone Caused by Sintilimab - Beware of Hypothyroid Myopathy","volume":"128","author":"Ni","year":"2020","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13217","article-title":"Pulmonary Fibrosis and Cytokine Release Syndrome After Hyperactivation With Sintilimab","volume":"45","author":"Hu","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-1310","article-title":"An Esophageal Cancer Case of Cytokine Release Syndrome With Multiple-Organ Injury Induced by an Anti-PD-1 Drug: A Case Report","volume":"9","author":"Gao","year":"2020","journal-title":"Ann Palliat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.21037\/atm.2020.01.79","article-title":"Myositis-Myasthenia Gravis Overlap Syndrome Complicated With Myasthenia Crisis and Myocarditis Associated With Anti-Programmed Cell Death-1 (Sintilimab) Therapy for Lung Adenocarcinoma","volume":"1","author":"Xing","year":"2020","journal-title":"Ann Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000314","article-title":"Paraneoplastic Encephalitis and Enteric Neuropathy Associated With Anti-Hu Antibody in a Patient Following","volume":"43","author":"Kang","year":"2020","journal-title":"J\u00a0Immunother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220947141","article-title":"Tofacitinib for Treatment in Immune-Mediated Myocarditis: The First Reported Cases","volume":"27","author":"Liu","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000958","article-title":"Dermoscopic Features of Acutely Exacerbated Plaque Psoriasis Induced by Anti-Programmed Death-1 for Lung Cancer","volume":"133","author":"Sui","year":"2020","journal-title":"Chin (Engl)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000025795","article-title":"Sintilimab Induced Diabetic Ketoacidosis in a Patient With Small Cell Lung Cancer","volume":"100","author":"Huang","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13967","article-title":"Severe Immune-Related Hyperthermia Followed by Immune-Related Pneumonitis With PD-1 Inhibitor (Sintilimab) in Small Cell Lung Cancer: A Case Report","volume":"12","author":"Li","year":"2021","journal-title":"Thorac Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13256-020-02619-y","article-title":"A False Alarm of COVID\u221219 Pneumonia in Lung Cancer With Anti\u2212PD\u22121 Related Pneumonitis: A Case Report and Review of the Literature","volume":"15","author":"Dai","year":"2021","journal-title":"J Med Case Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.21037\/apm-20-2449","article-title":"Immune Checkpoint Inhibitor-Induced Myocarditis in Lung Cancer Patients: A Case Report of Sintilimab-Induced Myocarditis and a Review of the Literature","volume":"10","author":"Bi","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001163","article-title":"Complete Pathological Response With Diabetic Ketoacidosis to the Combination of Sintilimab and Anlotinib in an Unresectable Hepatocellular Carcinoma Patient: A Case Report","volume":"33","author":"Fu","year":"2021","journal-title":"Anticancer Drugs"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.10.014","article-title":"Immune-Related Adverse Events Predict the Therapeutic Efficacy of Anti\u2013PD-1 Antibodies in Cancer Patients","volume":"109","author":"Rogado","year":"2019","journal-title":"Eur J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation Between Immune-Related Adverse Events and E Fficacy in Non- Small Cell Lung Cancer Treated With Nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"key":"B33","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"key":"B34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.critrevonc.2017.10.009","article-title":"Concomitant Use of Corticosteroids and Immune Checkpoint Inhibitors in Patients With Hematologic or Solid Neoplasms: A Systematic Review","volume":"120","author":"Garant","year":"2017","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4103\/CRST.CRST_88_19","article-title":"Concomitant Use of Corticosteroids and Immune Checkpoint Inhibitors in Patients With Solid Neoplasms: A Real-World Experience From a Tertiary Cancer Center","volume":"2","author":"Kapoor","year":"2019","journal-title":"Cancer Res Stat Treat"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non\u2013Small-Cell Lung Cancer","volume":"36","author":"Arbour","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse Effects of Immune-Checkpoint Inhibitors: Epidemiology, Management and Surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.757069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T11:57:28Z","timestamp":1640260648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.757069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":37,"alternative-id":["10.3389\/fonc.2021.757069"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.757069","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"article-number":"757069"}}